Zura Bio Ltd (ZURA) Stock Price, Quote & News

Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development. It is also developing Torudokimab (ZB-880), a monoclonal antibody that ne...

Industry: Biotechnology

Sector: Healthcare

Phone: 702 825 9872

Website: zurabio.com

Address:

1489 W. Warm Springs Road, Suite 110, Henderson, United States

AtomicAIerts Dec. 5 at 11:45 AM

$ZURA AtomicAlerts Scalp Alert Direction: SHORT Entry: $3.87 TP1: $3.17 | TP2: $2.47 | TP3: $1.77 Stop Loss: $4.47 👉 https://atomicalerts.com

0 · Reply

Iightning Dec. 2 at 2:21 AM

**1ightning® Premium Options Alert (Actionable)** **Ticker:** $ZURA **Contract:** Dec 19 $2.5C **Entry:** 1.26 **Exit:** 1.85 **Return:** **+47.13% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**

0 · Reply

StockConsultant Nov. 26 at 1:00 PM

$ZURA Zura Bio stock watch, pullback to 3.76 support area with high trade quality at https://stockconsultant.com/?ZURA

0 · Reply

Iightning Nov. 26 at 5:17 AM

1ightning® Options Trade Alert (Actionable) | Buy $ZURA Dec 19 $5 Call | Enter: $0.20 Exit: $0.30 | Profit: 47.74% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 3:25 PM

1ightning® Options Trade Alert (Actionable) | Buy $ZURA Dec 19 $5 Call | Enter: $0.20 Exit: $0.30 | Profit: 47.74% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 4:20 AM

1ightning® Options Trade Alert (Actionable) | Buy $ZURA Dec 19 $5 Call | Enter: $0.20 Exit: $0.30 | Profit: 47.74% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 22 at 1:31 AM

1ightning® Options Trade Alert (Actionable) | Buy $ZURA Dec 19 $5 Call | Enter: $0.46 Exit: $0.86 | Profit: 86.49% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 21 at 4:53 AM

1ightning® Options Trade Alert (Actionable) | Buy $ZURA Dec 19 $5 Call | Enter: $0.46 Exit: $0.86 | Profit: 86.49% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 20 at 2:36 AM

1ightning® Options Trade Alert (Actionable) | Buy $ZURA Dec 19 $5 Call | Enter: $0.46 Exit: $0.86 | Profit: 86.49% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 19 at 10:28 AM

1ightning® Options Trade Alert (Actionable) | Buy $ZURA Dec 19 $5 Call | Enter: $0.46 Exit: $0.86 | Profit: 86.49% ROI | https://1ightning.com

0 · Reply

Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates

Aug 20, 2025, 6:30 AM EDT - 3 months ago

Zura Bio to Participate in the Cantor Fitzgerald Global Healthcare Conference

Aug 14, 2025, 8:15 AM EDT - 4 months ago

Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates

Jul 17, 2025, 4:30 PM EDT - 5 months ago

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 1, 2025, 6:30 AM EDT - 5 months ago

Zura Bio Announces Chief Financial Officer Transition

May 27, 2025, 6:30 AM EDT - 6 months ago

Zura Bio to Present at the Jefferies Global Healthcare Conference

May 20, 2025, 6:30 AM EDT - 7 months ago

Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

May 8, 2025, 6:30 AM EDT - 7 months ago

Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates

Mar 25, 2025, 6:30 AM EDT - 9 months ago

Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

Feb 24, 2025, 6:30 AM EST - 10 months ago

Zura Bio to Present at the Leerink Partners Global Healthcare Conference

Dec 23, 2024, 6:30 AM EST - 1 year ago

Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis

Nov 25, 2024, 6:30 AM EST - 1 year ago

Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 14, 2024, 4:30 PM EST - 1 year ago

Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis

Nov 7, 2024, 6:30 AM EST - 1 year ago

Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Oct 30, 2024, 6:30 AM EDT - 1 year ago

Zura Bio to Participate in Two Upcoming Investor Conferences in November

Sep 3, 2024, 6:00 AM EDT - 1 year ago

CPS HR Consulting Partners with GovInvest to Revolutionize Compensation Consulting with Advanced Technology

OGI

Sep 3, 2024, 6:00 AM EDT - 1 year ago

Zura Bio to Present at Three Upcoming Investor Conferences in September

Aug 13, 2024, 9:21 AM EDT - 1 year ago

Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 12, 2024, 4:05 PM EDT - 1 year ago

Zura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding Warrants

Aug 9, 2024, 4:05 PM EDT - 1 year ago

Zura Bio Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to its Warrants

Jul 12, 2024, 6:10 AM EDT - 1 year ago

Zura Bio Commences Warrant Exchange Offer and Consent Solicitation

Jun 14, 2024, 6:00 AM EDT - 1 year ago

Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024

Jun 6, 2024, 6:00 AM EDT - 1 year ago

Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology

Jun 3, 2024, 6:00 AM EDT - 1 year ago

Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024

May 29, 2024, 6:00 AM EDT - 1 year ago

Zura Bio Announces Participation in June Investor Conferences

May 9, 2024, 6:00 AM EDT - 1 year ago

Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 18, 2024, 9:22 AM EDT - 1 year ago

Zura Bio Announces Oversubscribed $112.5 Million Private Placement

Apr 8, 2024, 6:00 AM EDT - 1 year ago

Zura Bio Announces Robert Lisicki as CEO and Director

Mar 28, 2024, 6:00 AM EDT - 1 year ago

Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer

Mar 4, 2024, 6:00 AM EST - 1 year ago

Zura Bio Announces Participation at March Conferences

Feb 2, 2024, 6:00 AM EST - 2 years ago

Zura Bio Announces Participation at February Investor Conferences

Jan 8, 2024, 6:00 AM EST - 2 years ago

Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO

Jan 3, 2024, 6:00 AM EST - 2 years ago

Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology Summit

Dec 4, 2023, 6:00 AM EST - 2 years ago

Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok

Nov 14, 2023, 6:00 AM EST - 2 years ago

Zura Bio Appoints Arnout Ploos van Amstel to its Board of Directors

Nov 13, 2023, 6:30 AM EST - 2 years ago

Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Sep 12, 2023, 5:00 AM EDT - 2 years ago

Zura Bio Enters into Sponsored Research Agreement with Benaroya Research Institute

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Zura Bio Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Jun 23, 2023, 6:30 AM EDT - 2 years ago

Zura Bio to Join the Russell 2000® and Russell 3000® Indexes

Jun 20, 2023, 5:33 PM EDT - 2 years ago

Why Shares of Zura Bio Climbed Tuesday

Jun 6, 2023, 4:00 AM EDT - 2 years ago

Zura Bio Completes Approximately $80 Million Financing with the Focus on Advancing ZB-106, a Potential First-in-class Anti-IL-17 and Anti-BAFF Dual Antagonist

Apr 27, 2023, 7:39 AM EDT - 2 years ago

Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune Diseases

Apr 14, 2023, 5:00 AM EDT - 2 years ago

Zura Bio Announces Appointment of Chief Scientific Officer

Mar 21, 2023, 6:13 AM EDT - 2 years ago

Zura Bio Limited Announces Closing of Business Combination with JATT Acquisition Corp

Mar 16, 2023, 4:17 PM EDT - 2 years ago

JATT Acquisition Corp Shareholders Approve Proposed Business Combination with Zura Bio Limited

AtomicAIerts Dec. 5 at 11:45 AM

$ZURA AtomicAlerts Scalp Alert Direction: SHORT Entry: $3.87 TP1: $3.17 | TP2: $2.47 | TP3: $1.77 Stop Loss: $4.47 👉 https://atomicalerts.com

0 · Reply

Iightning Dec. 2 at 2:21 AM

0 · Reply

StockConsultant Nov. 26 at 1:00 PM

$ZURA Zura Bio stock watch, pullback to 3.76 support area with high trade quality at https://stockconsultant.com/?ZURA

0 · Reply

Iightning Nov. 26 at 5:17 AM

1ightning® Options Trade Alert (Actionable) | Buy $ZURA Dec 19 $5 Call | Enter: $0.20 Exit: $0.30 | Profit: 47.74% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 3:25 PM

1ightning® Options Trade Alert (Actionable) | Buy $ZURA Dec 19 $5 Call | Enter: $0.20 Exit: $0.30 | Profit: 47.74% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 4:20 AM

1ightning® Options Trade Alert (Actionable) | Buy $ZURA Dec 19 $5 Call | Enter: $0.20 Exit: $0.30 | Profit: 47.74% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 22 at 1:31 AM

1ightning® Options Trade Alert (Actionable) | Buy $ZURA Dec 19 $5 Call | Enter: $0.46 Exit: $0.86 | Profit: 86.49% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 21 at 4:53 AM

1ightning® Options Trade Alert (Actionable) | Buy $ZURA Dec 19 $5 Call | Enter: $0.46 Exit: $0.86 | Profit: 86.49% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 20 at 2:36 AM

1ightning® Options Trade Alert (Actionable) | Buy $ZURA Dec 19 $5 Call | Enter: $0.46 Exit: $0.86 | Profit: 86.49% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 19 at 10:28 AM

1ightning® Options Trade Alert (Actionable) | Buy $ZURA Dec 19 $5 Call | Enter: $0.46 Exit: $0.86 | Profit: 86.49% ROI | https://1ightning.com

0 · Reply

Trizzie0805 Nov. 16 at 5:26 PM

Some long term swings! Charts setting up and prime in the weekly chart. Swinging $ZURA acending triangle forming key break out above $4.68 Swinging $RIVN will buy any dip closer to $13 range, looking for the reversal. Swinging $INVE too! Great reversals!

0 · Reply

JarvisFlow Nov. 14 at 8:55 PM

Chardan Capital has updated their rating for Zura Bio ( $ZURA ) to Buy with a price target of 10.

0 · Reply

d_risk Nov. 13 at 1:30 PM

$ZURA - Zura Bio Limited Class A Ordinary Shares - 10Q - Updated Risk Factors Zura flags heightened regulatory disruption risks from agency shutdowns, new uncertainties in clinical trial outcomes, intensifying competition, potential adverse impacts from healthcare reforms, stricter data privacy compliance challenges, and dependence on attracting and retaining key personnel. #Biotechnology #DataPrivacy #HealthcareReform #ClinicalTrials #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/ZURA/10-Q/2025-11-13

0 · Reply

JarvisFlow Nov. 13 at 11:12 AM

Clear Street updates rating for Zura Bio ( $ZURA ) to Buy, target set at 18.

0 · Reply

CAN_2409 Nov. 12 at 10:58 AM

$ZURA survival data at CADL is huge!

0 · Reply

SadyK189 Nov. 12 at 2:29 AM

Top Stocks to watch tomorrow 2 / 2: $RIVN $LUCY $IRWD $ZURA $XBIT RIVN: Looking good on daily chart. 16.10 - 16.60 is acting as key support zone. Next key level to test is 19.60 - 20.10. Overall it has long term potential of 24+ ZURA: Good close of daily candle. Key support at 3.4 - 3.8. Next key level to test is 4.95 - 5.30. Currently at 4.41. IRWD is trending nicely on daily chart. 2.15 - 2.35 is acting as key support zone. Next key level to test is 3.35 - 3.55. Currently at 2.95 LUCY: Good close of 4hours candle. Key support at 1.55 - 1.70. Next key level to test is 2.6 - 2.9. Currently at 2.17 XBIT tried to clear stiff resistance of 3.3 - 3.6 zone today but got rejected. Currently at 2.83. It may test this zone again.

0 · Reply